Device for in vivo delivery of bioactive agents and method of manufacture thereof

• US 9,107,605 B2
• Filed: 09/09/2004
• Issued: 08/18/2015
• Est. Priority Date: 11/17/2000
• Status: Active Grant

• Current Assignee: Vactronix Scientific, LLC
• Original Assignee: Advanced Bio Prosthetic Surfaces, Ltd.
• Inventors: Boyle, Christopher T., Bailey, Steven R., Marton, Denes, Banas, Christopher E.
• Primary Examiner(s): Sweet, Thomas J
• Assistant Examiner(s): MILLER, CHERYL L
• Application Number:
  US10/936,884
• Publication Number:
  US 20050186241A1
• Time in Patent Office: 3,995 Days
• Field of Search: 623/1.39, 623 142- 145, 623/1.12
• US Class Current: 1/1
• CPC Class Codes: A61B 5/01 Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue clinical contact thermometers G01K13/20
• CPC Class Codes: A61B 5/02055 Simultaneously evaluating both cardiovascular condition and temperature
• CPC Class Codes: A61B 5/021 Measuring pressure in heart or blood vessels A61B5/0205 takes precedence
• CPC Class Codes: A61B 5/0215 by means inserted into the body catheters A61M25/00
• CPC Class Codes: A61B 5/026 Measuring blood flow A61B3/1233, A61B3/1241 take precedence
• CPC Class Codes: A61B 5/076 Permanent implantations telemetry using implanted circuitry A61B5/0031; implanted stimulators for therapy A61N1/3605, A61N1/362, A61N1/372
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61B 5/6862 Stents
• CPC Class Codes: A61B 5/6876 Blood vessel
• CPC Class Codes: A61F 2/07 Stent-grafts
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2/86 Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2002/91533 characterised by the phase between adjacent bands
• CPC Class Codes: A61F 2002/91541 Adjacent bands are arranged out of phase
• CPC Class Codes: A61F 2002/91558 connected peak to peak
• CPC Class Codes: A61F 2210/0076 multilayered, e.g. laminated structures
• CPC Class Codes: A61F 2240/001 Designing or manufacturing processes
• CPC Class Codes: A61F 2250/0001 Means for transferring electromagnetic energy to implants
• CPC Class Codes: A61F 2250/0067 : Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 2250/0068 : the pharmaceutical product being in a reservoir
• CPC Class Codes: A61L 2300/602 : Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 27/04 : Metals or alloys
• CPC Class Codes: A61L 27/54 : Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/022 : Metals or alloys
• CPC Class Codes: A61L 31/16 : Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

The present invention consists of an implantable structural element for in vivo controlled delivery of bioactive active agents to a situs in a body. The implantable structural element may be configured as an implantable prosthesis, such as an endoluminal stent, cardiac valve, osteal implant or the like, which serves a dual function of being prosthetic and a carrier for a bioactive agent. Control over elution of the bioactive agents occurs through a plurality of cantilever-like cover members which prevent drug elution until an endogenous or exogenous stimulus causes the cover members to open and permit drug elution.

Claims

1. An implantable drug-eluting medical device, comprising a first stent member having a plurality of wall surfaces defining a z-axis thickness of the first stent member to form the implantable drug-eluting medical device, at least a first internal chamber enclosed entirely within the z-axis thickness of the first stent member, at least a first of a plurality of openings communicating between the first internal chamber and at least a first of the plurality of wall surfaces and through a portion of the z-axis thickness of the first stent member, a first bioactive agent disposed within the first internal chamber, and a plurality of metal cover members disposed upon the first of the plurality of wall surfaces, at least a first of the plurality of metal cover members associated with the first opening, each of the plurality of metal cover members having a first position which covers and occludes an associated one of the plurality of openings and a second position which uncovers said associated opening, wherein one of shape memory properties or superelastic properties of the plurality of metal cover members actuate the plurality of metal cover members to pivot between the first position and the second position upon encountering a defined stimulus, and wherein in the second position each of the plurality of metal cover members projects outwardly from the first stent member.

2. The implantable drug-eluting medical device according to claim 1, wherein the stimulus is an exogenous stimulus applied transcutaneously to the medical device.

3. The implantable drug-eluting medical device according to claim 1, wherein the stimulus is selected from the group consisting of endogenous physical, electrical, thermal or chemical stimuli.

4. The implantable drug-eluting medical device according to claim 1, wherein the first stent member is selected from the group consisting of a stent, covered stent and vascular graft.

5. The implantable drug-eluting medical device according to claim 1, wherein the first stent member comprises a stent having a plurality of interconnected individual structural elements, at least some of the plurality of interconnected individual structural elements having the at least a first internal chamber, wherein each of the at least a first internal chamber has at least one of the plurality of openings communicating between the at least a first internal chamber and external the structural elements within which the at least a first chamber is disposed through a portion of the thickness of the structural elements, the at least one bioactive agent disposed within the at least a first internal chamber, and at least one of the plurality of metal cover members operably associated with the at least one of the plurality of openings.

6. The implantable drug-eluting medical device according to claim 1, wherein the first stent member and the plurality of metal cover members each comprise a material selected from the group consisting of nickel-titanium alloy, nickel-titanium-tantalum alloy, and chromium-cobalt alloy.

7. The implantable drug-eluting medical device according to claim 1, wherein the first bioactive agent comprises a pharmacologically active agent selected from the group consisting of antibiotic drugs, antiviral drugs, neoplastic agents, steroids, fibronectin, anti-clotting drugs, anti-platelet function drugs, drugs which prevent smooth muscle cell growth on inner surface wall of vessel, heparin, heparin fragments, aspirin, coumadin, tissue plasminogen activator, urokinase, hirudin, streptokinase, antiproliferative agents, antioxidants, antimetabolites, thromboxane inhibitors, non-steroidal and steroidal anti-inflammatory drugs, immunosuppresents, beta and calcium channel blockers, genetic materials including DNA and RNA fragments, complete expression genes, antibodies, lymphokines, growth factors, vascular endothelial growth factor, fibroblast growth factor, prostaglandins, leukotrienes, laminin, elastin, collagen, nitric oxide, integrins, paclitaxel, taxol, rapamycin, rapamycin derivatives and analogues, sirolimus, rapamune, tacrolimus, dexamethasone, everolimus, ABT-578 and growth factors.

8. An endoluminal stent, comprising a generally tubular member having a central lumen passing longitudinally through the tubular member and open at opposing ends of the tubular member, a luminal surface and an abluminal surface and a wall thickness defined therebetween, at least one internal chamber defined entirely within the wall thickness in at least some portions of the tubular member, a plurality of openings communicating between the at least one internal chamber and at least one of the luminal surface or abluminal surface through at least a portion of the wall thickness, at least one bioactive agent disposed in the at least one internal chamber and a plurality of metal cover members operably associated with the plurality of openings and each metal cover member having a closed position which occludes an associated one of the plurality of openings and an open position which permits the at least one bioactive agent to elute from the at least one internal chamber and through the associated one of the plurality of openings, wherein shape memory properties or superelastic properties of the plurality of metal cover members actuate the plurality of metal cover members to pivot between the closed position and the open position upon encountering a defined stimulus, and wherein in the open position each metal cover member projects outwardly from the luminal surface or the abluminal surface to a point outside the wall thickness.

9. The endoluminal stent according to claim 8, wherein the tubular member and the plurality of metal cover members comprise a material selected from the group consisting of nickel titanium alloy, and chromium-cobalt alloy.

10. The endoluminal stent according to claim 9, wherein at least one of the tubular member and the plurality of metal cover members are fabricated of at least one biocompatible thin metallic film.

11. The endoluminal stent according to claim 8, wherein the at least one bioactive agent comprises a pharmacologically active agent selected from the group consisting of antibiotic drugs, antiviral drugs, neoplastic agents, steroids, fibronectin, anti-clotting drugs, anti-platelet function drugs, drugs which prevent smooth muscle cell growth on inner surface wall of vessel, heparin, heparin fragments, aspirin, coumadin, tissue plasminogen activator, urokinase, hirudin, streptokinase, antiproliferative agents, antioxidants, antimetabolites, thromboxane inhibitors, non-steroidal and steroidal anti-inflammatory drugs, immunosuppresents, beta and calcium channel blockers, genetic materials including DNA and RNA fragments, complete expression genes, antibodies, lymphokines, growth factors, vascular endothelial growth factor, fibroblast growth factor, prostaglandins, leukotrienes, laminin, elastin, collagen, nitric oxide, integrins, paclitaxel, taxol, rapamycin, rapamycin derivatives and analogues, sirolimus, rapamune, tacrolimus, dexamethasone, everolimus, ABT-578 and growth factors.

12. The endoluminal stent according to claim 8, wherein the tubular member comprises a plurality of interconnected structural elements defining walls of the tubular member, a plurality of discontinuous interior chambers associated with at least some of the plurality of structural elements, the plurality of openings communicating between each of the plurality of discontinuous interior chambers and external the stent, the at least one bioactive agent disposed within the plurality of discontinuous interior chambers, and at least one of the plurality of metal cover members associated with the plurality of openings.

13. An implantable drug-eluting medical device, comprising:

a first metal layer having a first wall surface and a second wall surface,

a second metal layer disposed upon the second wall surface of the first metal layer, wherein the second metal layer defines at least a first internal chamber entirely enclosed by the second metal layer and the second wall surface of the first metal layer, and at least one of a plurality of openings communicating between the first internal chamber and external the second metal layer to form the implantable drug-eluting medical device;

a bioactive agent disposed within the first internal chamber; and

a third metal layer including a plurality of metal cover members disposed upon the second metal layer and associated with the plurality of openings, each of the plurality of metal cover members having a first position which covers and occludes an associated opening of the plurality of openings and a second position which uncovers the associated opening, wherein one of shape memory properties or superelastic properties of the plurality of metal cover members actuate the plurality of metal cover members to pivot between the first position and the second position upon encountering a defined stimulus, such that in the second position each metal cover member projects outwardly from the second metal layer.

14. The implantable drug-eluting medical device according to claim 13, wherein the stimulus is an exogenous stimulus applied transcutaneously to the medical device.

15. The implantable drug-eluting medical device according to claim 13, wherein the stimulus is selected from the group consisting of endogenous physical, electrical, thermal or chemical stimuli.

16. The implantable drug-eluting medical device according to claim 13, wherein the metal layers are selected from the group consisting of a stent, covered stent and vascular graft.

17. The implantable drug-eluting medical device according to claim 13, wherein each of the plurality of metal cover members is fabricated from a nickel titanium alloy or a chromium-cobalt alloy.